Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

Lipid-lowering Therapy Individualization

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01867203

Enrollment

Registered

2013-06-03

Start date

2017-08-01

Completion date

2019-09-01

Last updated

2021-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy

Brief summary

Patients needing lipid lowering therapy will be recruited before initiation of the treatment. For each patient, total and LDL cholesterol levels before start of therapy will be measured. One, three and six months after his/her first visit, when steady-state will be reached, for each included patient, the cholesterol levels will be re-assessed in order to evaluate the response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is to assess the association between patient's genotype and the response to statin therapy.

Interventions

OTHERGenotyping

DNA extraction from blood

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patient known to be compliant * Age \[25-80\] * treated with Atorvastatin, simvastatin, fluvastatin.

Exclusion criteria

* Pregnancy

Design outcomes

Primary

Measure	Time frame
Cholesterol levels-side effects	1 to 6 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026